CD99

CD99 antigen · P14209 · CD99 on Sugi Atlas →

1,419 patent compounds predicted against CD99, 1,236 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Clofarabine (SCHEMBL9040)	0.69	2/20
Clofarabine (SCHEMBL1467619)	0.69	2/20
Clofarabine (SCHEMBL2887297)	0.69	2/20
Clofarabine (SCHEMBL4384631)	0.69	2/20
Clofarabine (SCHEMBL4570563)	0.69	2/20
Clofarabine (SCHEMBL5975001)	0.69	2/20
Clofarabine (SCHEMBL10024090)	0.69	2/20
Clofarabine (SCHEMBL10026375)	0.69	2/20
Clofarabine (SCHEMBL12139443)	0.69	2/20
Clofarabine (SCHEMBL12595105)	0.69	2/20
Clofarabine (SCHEMBL12648615)	0.69	2/20
Clofarabine (SCHEMBL14682719)	0.69	2/20
Clofarabine (SCHEMBL15468200)	0.69	2/20
Clofarabine (SCHEMBL16767063)	0.69	2/20
Clofarabine (SCHEMBL16786348)	0.69	2/20
Clofarabine (SCHEMBL17560676)	0.69	2/20
Clofarabine (SCHEMBL17752021)	0.69	2/20
Clofarabine (SCHEMBL18516024)	0.69	2/20
SCHEMBL8744104	0.58	2/20
SCHEMBL8744111	0.58	2/20

Clinical trials — most relevant to CD99 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer	PHASE3	RECRUITING
Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease	PHASE2	UNKNOWN
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL	PHASE2	RECRUITING
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status	PHASE2	RECRUITING
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers	PHASE1	COMPLETED
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma	PHASE1	COMPLETED
Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.	PHASE1	UNKNOWN
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	PHASE1	COMPLETED
Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse	nan	RECRUITING
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis	nan	COMPLETED
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN	nan	UNKNOWN
Choosing a Preferred Serology Kit for Screening and Diagnosis of Celiac Disease	nan	COMPLETED
Clinical and Surgical Outcomes of Total Thyroidectomy in Basedow's Disease: the Effect of Lugol Solution	nan	UNKNOWN
The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients	nan	RECRUITING
Development and Validation of a Nomogram for Predicting Surgery in Newly-diagnosed Crohn's Disease: a Retrospective Cohort Study	nan	COMPLETED
Audit of the Spanish EURECCA Esophagogastric Cancer Registry	nan	COMPLETED
Detection of Plasma Circulating Tumor DNA in Gastric Cancer	nan	UNKNOWN
Serum and Peritoneal CEA and CA 19-9 for Gastric Adenocarcinoma	nan	COMPLETED
Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer	nan	NOT_YET_RECRUITING
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria	nan	COMPLETED
Effect of Cell Surface Markers and Lymphoid Cell Distribution on the Arterial Tissue Repair (ECLAR)	nan	UNKNOWN
Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer	nan	ACTIVE_NOT_RECRUITING
Autologous Keratinocyte Suspension Versus Adipose-Derived Stem Cell-Keratinocyte Suspension for Post-Burn Raw Area	nan	UNKNOWN
Evaluation of CEMIP in Pancreatic Cancer	nan	UNKNOWN
Expression of Aberrant CD Markers in Acute Leukemia:Retrospective Study in South Egypt Cancer Institute	nan	UNKNOWN
The Acute Effect of a Theacrine-based Supplement on Mobilization of Various Stem Cell Populations.	nan	COMPLETED
Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CD99 binder may also engage these)

Protein	Name	Similarity
Q8VCN6	—	0.992	Q8VCN6 →
Q5RE35	—	0.982	Q5RE35 →
Q6DBW9	—	0.981	Q6DBW9 →
A1A4K1	—	0.980	A1A4K1 →
B1H3G4	—	0.978	B1H3G4 →
Q8TCZ2	—	0.977	Q8TCZ2 →
P55808	—	0.976	P55808 →
Q8BIF0	—	0.975	Q8BIF0 →
Q8R1R5	—	0.972	Q8R1R5 →
Q3E965	—	0.969	Q3E965 →
O81775	—	0.968	O81775 →
Q9SW07	—	0.967	Q9SW07 →
Q6DBU1	—	0.967	Q6DBU1 →
Q9FK96	—	0.966	Q9FK96 →
O81483	—	0.966	O81483 →
Q9N4Y9	—	0.966	Q9N4Y9 →
Q9FHK9	—	0.966	Q9FHK9 →
Q9C7F7	—	0.965	Q9C7F7 →
Q94IK2	—	0.965	Q94IK2 →
Q9LXA7	—	0.965	Q9LXA7 →
Q9LI74	—	0.965	Q9LI74 →
Q9TSZ6	—	0.964	Q9TSZ6 →
Q93ZH7	—	0.964	Q93ZH7 →
Q6K678	—	0.964	Q6K678 →
Q8LJS2	—	0.964	Q8LJS2 →
P18764	—	0.964	P18764 →
Q5RAT9	—	0.964	Q5RAT9 →
Q22472	—	0.964	Q22472 →
Q28685	—	0.964	Q28685 →
Q9SD39	—	0.964	Q9SD39 →